Immuron (ASX:IMC; NASDAQ:IMRN) Advances Pipeline and Financial Metrics Ahead of FY26
Immuron Limited is progressing its oral antibody platform with a focus on infectious disease and gastrointestinal health. The company anticipates growth in financial indicators and pipeline advancements, including FDA-approved IMM-529 for recurrent infections.
Immuron Limited is advancing its clinical pipeline, notably with IMM-529, which has received FDA approval for Phase 2 trials as an adjunctive therapy for recurrent Clostridioides difficile infection. In FY26, the company reported revenue of A$4.18 million for the half-year ending December 2025, an increase from A$3.99 million year-over-year, with net assets rising to A$13.07 million.
AI-curated by TheiaOngoing financing from the US Department of Defense for oral therapeutics targeting Campylobacter and Shigella supports its R&D initiatives. The company projects that net sales and profits in the second half of FY26 will surpass previous levels, driven by its product pipeline and enhanced financial position.
Comments